📈 As the field of #RCC research continues to grow, researchers have conducted a real-world study to determine the impact of treatment patterns and costs for patients with mRCC through the use of integrated claims and clinical information:

RT @Uromigos: 🚨 Out now: Episode 384 features returning guest @Silke_Gillessen in a discussion on top studies to look forward to at @ASCO #…

⭐ We spoke with Ian Thompson, Jr., MD at @dsui_miami_uro's Urology On The Beach meeting on his recently published large dataset of long-term complications of #prostatecancer treatment. 📺 He explains the insights gained from the 25-year data:

⭐ At @dsui_miami_uro's Urology On The Beach meeting, Dr. @raveensyan highlights advancements in female pelvic medicine and reconstructive surgery, expanding on the progress that's been made in addressing gender-specific challenges in urologic #oncology:

❗️ New recommendations released by @ASCO have provided updates to guidelines on the use of germline and somatic genomic testing for patients with metastatic #prostatecancer, including repeat testing and optimal tissue type:

⭐ In a roundtable discussion on metastatic #prostatecancer moderated by Dr. Jacob Ark, Drs. John Finnie, Gautum Agarwal, Seth Strope, & David Bryan explore topics such as the diagnostic criteria for hormone-sensitive and castration-resistant disease:

💊 A recent retrospective, multicenter study has analyzed 1L treatment with PD-1 blockades combined with #cisplatin and #paclitaxel-based chemotherapy in patients with HR stage IV PSCC to determine the efficacy and safety of the combination treatment:

⭐ At @dsui_miami_uro's Urology On The Beach meeting, @RSanchez_Salas of the Division of Urology at @mcgillu details strategies to emphasize for selecting between focal therapy, active surveillance, and definitive treatments for localized #prostatecancer:

🔎 A recent retrospective analysis has longitudinally examined #ctDNA status and dynamics throughout surveillance and during TRM in patients with metastatic clear cell #RCC and non-clear cell RCC treated with #immunotherapy or targeted therapies:

🔬 A recent cross-sectional post hoc analysis has examined the staging information obtained by PSMA-PET/CT in a cohort eligible for the #EMBARK trial to see what findings are present in patients with HR recurrent #nmHSPC on conventional imaging:

🧪 The phase 2 LITESPARK-003 study has shown that the HIF-2α inhibitor #belzutifan combined with #cabozantinib for treatment-naive patients with advanced clear-cell #RCC can provide promising antitumor activity:

💊 New results from the phase 3 CREST trial have shown that the combination of #sasanlimab and BCG provides a significant improvement for patients with BCG-naive, high-risk #NMIBC over BCG alone. 👉 The study met its primary endpoint of EFS:

🚨 @Clarity_Pharma's 64Cu-SAR-bisPSMA imaging agent has received a Fast Track Designation by the @US_FDA for the detection of PSMA+ #prostatecancer in certain patients. ⭐ This milestone marks Clarity’s second FTD for 64Cu-SAR-bisPSMA:

🚨 New findings from the phase 3 TROPiCS-04 study have revealed that #chemotherapy provides better outcomes for patients with pretreated advanced #urothelialcarcinoma than #sacituzumab govitecan, as the study’s primary endpoint of improved OS was not met:

🔎 New research has analyzed the incidence and impact of #proteinuria in patients following radical and partial #nephrectomy. 👉 Learn how proteinuria was found to be significantly higher in patients who underwent radical nephrectomy:

🔎 Dr. Daniel Geynisman of @FoxChaseCancer discusses the rationale behind the phase 2 RETAIN 1 trial, aimed at evaluating how #MIBC is treated. 📺 The RETAIN trial explores whether certain patients can avoid invasive procedures such as chemoradiation:

RT @shilpaonc: ‼️ Pls support the @BladderCancerUS 2025 New Faces of Bladderca survey. The survey aims to understand the needs, challenge…

⭐ In our latest interview, we spoke with @AmirLebastchi on focal therapy for #prostatecancer, covering its historical evolution, current techniques and energy modalities, the critical roles of MRI and biomarkers in patient selection, and more:

📺 @MarkTysonMD, of @MayoClinic, discusses the data from cohort P of the BOND-003 trial, exploring the potential of cretostimogene grenadenorepvec in treating papillary-only BCG-unresponsive, non-muscle-invasive bladder cancer:

🔎 A recent long-term follow-up of participants in the #OLYMPUS trial included analysis of the outcomes of primary #chemoablation using the mitomycin reverse thermal gel UGN-101 for patients with low-grade #UTUC: